mRNA technology helped propel the development of some of the most successful drugs in pharma history — notably, the Comirnaty COVID-19 from Pfizer generated almost $56 billion in 2022 while Moderna’s Spikevax vaccine raked in $18.4 billion. But with demand for COVID-19 vaccines cooling, drug developers are aiming to extend the dominion of mRNA technology…

As obesity rates continue to soar across the globe, analysts anticipate that the market for anti-obesity drugs will skyrocket in the coming years. Goldman Sachs projects the market to be worth $44 billion by 2030. That’s an almost 16-fold expansion from its valuation of approximately $2.82 billion in 2022. Barclays is even more upbeat on…

2023 is shaping up to be a pivotal year for promising biotech startups. While the sector faced multiple waves of layoffs, a silver lining is evident: the growing maturity of AI and genomics technologies is fueling a new wave of startup advances, especially in drug development. Amidst the backdrop of that turbulence, a select group…